Virax Biolabs Group Limited (VRAX)

Compare

1.1400

+0.0600

+(5.56%)

At close: April 2 at 4:00:00 PM EDT

Virax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy Rating

H.C. Wainwright initiated coverage on Virax Biolabs Group Limited (NASDAQ:VRAX), a U.K.-based company focused on detecting immune responses and diagnosing viral diseases. Virax Biolabs is developing T cell-based test technologies to provide an immunology profiling platform. T-cell testing can be particularly effective in diagnosing and therapeutics for post-viral syndromes (such as Long COVID and other chronic conditions linked to immune dysregulation). Also Read: EXCLUSIVE: Virax Biolabs Says I

Benzinga 2 days ago

VRAX
+5.56%
Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes

Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today that it has started enrolling patients into its United Kingdom based, multi-center clinical study (NCT06731179).

PR Newswire 15 days ago

VRAX
+5.56%
Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting

Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced it has presented data evaluating the role of T-Cell dysfunction in post-acute infection syndromes (PAIS) at the World Immune Regulation Meeting (WIRM) in Davos, Switzerland.

PR Newswire 20 days ago

VRAX
+5.56%
Virax Biolabs to Present at 19th World Immune Regulation Meeting

Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that the company's management will present at the 19th World Immune Regulation Meeting (WIRM), which will take place March 12-15, 2025, in Davos, Switzerland.

PR Newswire 28 days ago

VRAX
+5.56%
Virax Biolabs Believes Technology Aligns with United States Department of Health and Human Services' Transparency Priority on Vaccine Efficacy

Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") believes that its technology aligns with the United States Department of Health and Human Services' commitment to prioritizing transparency on vaccine efficacy. This initiative is essential for empowering the public with the information needed to make informed health decisions.

PR Newswire last month

VRAX
+5.56%
EXCLUSIVE: Virax Biolabs Says Its Tech Fits RFK Jr.'s HHS Goals On Vaccine Transparency

On Thursday, Virax Biolabs Group Limited (NASDAQ:VRAX) said it supports the U.S. Department of Health and Human Services’ focus on vaccine efficacy transparency, emphasizing the need for accessible information to aid informed health decisions. The company underscores the role of transparency in understanding vaccine effectiveness and the impact of individual immune responses on vaccination outcomes. Also Read: EXCLUSIVE: Virax Biolabs Inks Distribution Pact To Commercialize ImmuneSelect Profilin

Benzinga last month

VRAX
+5.56%
Cosmos Health secures exclusive distribution agreement with Virax Biolabs

Cosmos Health (COSM) has entered into a distribution agreement with Virax Biolabs Group (VRAX) to distribute Virax-branded Avian Influenza Virus Real-Time PCR Kits across various major European markets and certain Gulf Cooperation Council countries. Specifically, Cosmos Health gains exclusive rights to distribute these kits in Greece and Cyprus, as well as non-exclusive rights in select European countries, including France, Portugal, Spain, The Netherlands, Belgium, Sweden, Finland, Denmark, Nor

TipRanks 2 months ago

COSM

VRAX
+5.56%
Virax Biolabs' CEO James Foster Issues Letter to Shareholders

Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases, today announced that Mr. James Foster, Chief Executive Officer of Virax, has issued a letter to shareholders outlining the Company's plans for 2025 and highlights recent accomplishments.

PR Newswire 3 months ago

VRAX
+5.56%
Virax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect Across the European Union, Norway, and Switzerland

Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that it has entered into a non-exclusive distribution agreement with French company Tebubio to expand the distribution of its ImmuneSelect Research Use portfolio into countries in the European Union, as well as in Norway and Switzerland.

PR Newswire 3 months ago

VRAX
+5.56%
Top Midday Gainers

Top Midday Gainers

PREMIUM
MT Newswires 5 months ago

LRHC

VRAX
+5.56%
MSFT
Virax Biolabs Announces Distribution Agreement with Europa Biosite to Commercialize ImmuneSelect in the United Kingdom and Ireland

Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that it has entered into a distribution agreement with Europa Biosite to commercialize the company's ImmuneSelect Research Use portfolio in the United Kingdom and Ireland through its wholly owned subsidiary Cambridge Bioscience.

PR Newswire 5 months ago

VRAX
+5.56%
EXCLUSIVE: Virax Biolabs Inks Distribution Pact To Commercialize ImmuneSelect Profiling Solutions In UK And Ireland

On Wednesday, Virax Biolabs Group Limited (NASDAQ:VRAX) entered into a distribution agreement with Europa Biosite to commercialize the company's ImmuneSelect Research Use portfolio in the U.K. and Ireland through its wholly-owned subsidiary Cambridge Bioscience. "ImmuneSelect is an important suite of profiling solutions for assessing adaptive immunity...," said James Foster, CEO of Virax Biolabs. Also Read: Virax Biolabs Announces Stock Offering: What To Know. "We believe this partnership will m

Benzinga 5 months ago

VRAX
+5.56%
Virax Biolabs Announces Extension of Existing Exclusive Distribution Agreement to Market Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits with Cosmos Health Inc.

Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that it has entered into an extension of its already existing exclusive distribution agreement with Cosmos Health Inc. (Nasdaq: COSM) ("Cosmos") to commercialize Mpox Virus Real-Time PCR Detection Kits in countries in the Gulf Cooperation Council ("GCC"). It had previously signed an agreement for e

PR Newswire 6 months ago

VRAX
+5.56%
COSM
Virax Biolabs Presents at H.C. Wainwright's 26th Annual Global Investment Conference

Virax Biolabs ("Virax" or the "Company") (NASDAQ: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that Chief Operating Officer, Dr Nigel McCracken is presenting at H.C. Wainwright's 26th Annual Global Investment Conference, held in New York, NY and that the pre-recorded and on-demand presentation is now available.

PR Newswire 6 months ago

VRAX
+5.56%
Virax Biolabs to Participate at 7th European Congress of Immunology

Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today it will be hosting a booth at the 7th European Congress of Immunology (ECI), which is taking place from September 1 - 4, 2024, in Dublin, Ireland.

PR Newswire 6 months ago

VRAX
+5.56%
Virax Biolabs Announces Distribution Agreement to Commercialize Mpox (formerly Monkeypox) Virus RT-PCR Detection Kits in Europe and the Middle East

Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that it has entered into a distribution agreement with a supplier of (RT) PCR Mpox virus detection kits to commercialize them in 13 European countries as well as members of the Gulf Cooperation Council ("GCC") including Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates.

PR Newswire 7 months ago

VRAX
+5.56%
EXCLUSIVE: Virax Biolabs Inks Distribution Pact For Mpox Diagnostic Kits In Europe And Middle East

Wednesday, Virax Biolabs Group Limited (NASDAQ:VRAX) entered into a distribution agreement with a supplier of (RT) PCR Mpox virus detection kits to commercialize them in some European and Gulf countries. The RT PCR Mpox virus detection kits are approved for sale in Europe and also authorized by the Medicines and Healthcare Products Regulatory Agency, the product regulatory agency for the United Kingdom. Earlier this month, the World Health Organization issued an international public health emerg

Benzinga 7 months ago

VRAX
+5.56%
Virax Biolabs Group Limited Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares

Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced the closing of its previously announced registered direct offering for the purchase and sale of an aggregate of 1,108,892 of its ordinary shares at a purchase price of $4.50 per share.

PR Newswire 7 months ago

VRAX
+5.56%
Virax Biolabs Group Limited Announces $5 Million Registered Direct Offering of Ordinary Shares

Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,108,892 of its ordinary shares at a purchase price of $4.50 per share in a registered direct offering. The closing of the offering is expected to occur on or about August 23, 2024, subject to the satisfac

PR Newswire 7 months ago

VRAX
+5.56%
Zacks Investment Ideas feature highlights: Virax Biolabs Group, GeoVax Labs, Applied DNA Sciences and Emergent BioSolutions

Virax Biolabs Group, GeoVax Labs, Applied DNA Sciences and Emergent BioSolutions have been highlighted in this Investment Ideas article.

Zacks 7 months ago

VRAX
+5.56%

Performance Overview

Return	VRAX	S&P 500 (^GSPC)
YTD	-49.33%	-3.58%
1-Year	+45.41%	+8.94%
3-Year	-99.43%	+24.75%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Virax Biolabs Group Limited (VRAX)

Virax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy Rating

Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes

Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting

Virax Biolabs to Present at 19th World Immune Regulation Meeting

Virax Biolabs Believes Technology Aligns with United States Department of Health and Human Services' Transparency Priority on Vaccine Efficacy

EXCLUSIVE: Virax Biolabs Says Its Tech Fits RFK Jr.'s HHS Goals On Vaccine Transparency

Cosmos Health secures exclusive distribution agreement with Virax Biolabs

Virax Biolabs' CEO James Foster Issues Letter to Shareholders

Virax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect Across the European Union, Norway, and Switzerland

Top Midday Gainers

Virax Biolabs Announces Distribution Agreement with Europa Biosite to Commercialize ImmuneSelect in the United Kingdom and Ireland

EXCLUSIVE: Virax Biolabs Inks Distribution Pact To Commercialize ImmuneSelect Profiling Solutions In UK And Ireland

Virax Biolabs Announces Extension of Existing Exclusive Distribution Agreement to Market Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits with Cosmos Health Inc.

Virax Biolabs Presents at H.C. Wainwright's 26th Annual Global Investment Conference

Virax Biolabs to Participate at 7th European Congress of Immunology

Virax Biolabs Announces Distribution Agreement to Commercialize Mpox (formerly Monkeypox) Virus RT-PCR Detection Kits in Europe and the Middle East

EXCLUSIVE: Virax Biolabs Inks Distribution Pact For Mpox Diagnostic Kits In Europe And Middle East

Virax Biolabs Group Limited Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares

Virax Biolabs Group Limited Announces $5 Million Registered Direct Offering of Ordinary Shares

Zacks Investment Ideas feature highlights: Virax Biolabs Group, GeoVax Labs, Applied DNA Sciences and Emergent BioSolutions

Performance Overview